$GOSS

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Gossamer Bio Appoints Greg Ciongoli to Board of Directors SAN DIEGO — (BUSINESS WIRE) — September 16, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatmen

Gossamer Bio (GOSS) fell 6.14% to $10.69 after completing a 1-for-80 reverse stock split. The company's shares are now trading on a split-adjusted basis. The stock's 52-week range is $9.10 to $309.60.

Gossamer Bio (GOSS) announced a 1-for-80 reverse stock split and reduced authorized shares to 50M to comply with Nasdaq's minimum bid price requirement. The split is effective September 10, 2026, with trading adjustments on September 11, 2026. Convertible notes, warrants, and equity awards will be proportionately adjusted.

Gossamer Bio (GOSS) filed a Form D notice with the SEC, raising $125M through private securities offerings. The biotech firm, based in San Diego, did not disclose revenue. The offering includes options, warrants, and other rights to acquire securities. Leerink Partners LLC is involved as a broker-dealer.

Gossamer Bio (GOSS) plans a stock issuance that could dilute current holders. The company issued pre-funded warrants for up to 178.7M shares and may issue more upon FDA milestones, requiring shareholder approval. The issuance is tied to a private placement involving executive officers and directors.

Gossamer Bio (GOSS) announced a private placement with up to $250M in gross proceeds, but only $25M is expected upfront. The remaining funds are contingent on regulatory milestones for seralutinib, a drug for pulmonary arterial hypertension. The company ended June with $57M in cash, expecting the initial $25M to improve near-term liquidity but not fully secure its runway.

Gossamer Bio (GOSS) granted its CCO 5.8M stock options. 50% vest upon FDA approval of seralutinib, with the rest vesting monthly over 24 months. If no approval within 2 years, vesting begins monthly over 24 months. Options expire in 2036 with a $0.175 exercise price.

Gossamer Bio secured up to $250M in financing, including $150M committed capital and $100M in potential warrants, to fund seralutinib through FDA approval for pulmonary arterial hypertension. The company plans to use the funds for clinical trials, potential commercialization, and corporate needs, aiming to submit an NDA in September 2026. Investors include EcoR1 Capital, 683 Capital Partners, and others.

Gossamer Bio (GOSS) plans a private placement of up to $250M, including $150M committed capital. The deal involves new and existing investors and is contingent on FDA actions for seralutinib. Latham & Watkins advised the company. The financing follows Gossamer's reacquisition of seralutinib rights and precedes its planned NDA submission in September 2026.

Gossamer Bio (GOSS) shares fell 5.59% after announcing a $250M financing deal tied to FDA milestones for seralutinib. The company plans to submit an NDA in September, with $150M committed and $100M contingent on approval. Analysts maintain Buy ratings with targets up to $4. Q2 revenue was $9.2M, R&D expenses $26.4M.